A Non-Interventional, Multicenter, Historical Cohort Study of Intravitreal Ranibizumab Treatment and Visual Outcomes in Real-World Settings
Phase of Trial: Phase IV
Latest Information Update: 30 May 2018
Price : $35 *
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions; Therapeutic Use
- Acronyms UNCOVER
- Sponsors Novartis Pharma A.G.
- 30 May 2018 New trial record
- 01 May 2018 Results published in the Graefes Archive for Clinical and Experimental Ophthalmology.